BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36129635)

  • 1. A Novel Immunotoxin Targeting Epithelial Cell Adhesion Molecule Using Single Domain Antibody Fused to Diphtheria Toxin.
    Roshan R; Naderi S; Behdani M; Ahangari Cohan R; Kazemi-Lomedasht F
    Mol Biotechnol; 2023 Apr; 65(4):637-644. PubMed ID: 36129635
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Granzyme B-based cytolytic fusion protein targeting EpCAM specifically kills triple negative breast cancer cells in vitro and inhibits tumor growth in a subcutaneous mouse tumor model.
    Amoury M; Kolberg K; Pham AT; Hristodorov D; Mladenov R; Di Fiore S; Helfrich W; Kiessling F; Fischer R; Pardo A; Thepen T; Hussain AF; Nachreiner T; Barth S
    Cancer Lett; 2016 Mar; 372(2):201-9. PubMed ID: 26806809
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Increasing anticarcinoma activity of an anti-erbB2 recombinant immunotoxin by the addition of an anti-EpCAM sFv.
    Stish BJ; Chen H; Shu Y; Panoskaltsis-Mortari A; Vallera DA
    Clin Cancer Res; 2007 May; 13(10):3058-67. PubMed ID: 17505009
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Production and Conjugation of Truncated Recombinant Diphtheria Toxin to VEGFR-2 Specific Nanobody and Evaluation of its Cytotoxic Effect on PC-3 Cell Line.
    Shajari S; Farajollahi MM; Behdani M; Tarighi P
    Mol Biotechnol; 2022 Nov; 64(11):1218-1226. PubMed ID: 35478310
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of neovascularisation in human endothelial cells using anti NRP-1 nanobody fused to truncated form of diphtheria toxin as a novel immunotoxin.
    Naderi S; Roshan R; Behdani M; Kazemi-Lomedasht F
    Immunopharmacol Immunotoxicol; 2021 Apr; 43(2):230-238. PubMed ID: 33657977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Construction, expression, and characterization of a recombinant immunotoxin targeting EpCAM.
    Lv M; Qiu F; Li T; Sun Y; Zhang C; Zhu P; Qi X; Wan J; Yang K; Zhang K
    Mediators Inflamm; 2015; 2015():460264. PubMed ID: 25960617
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of amanitin-conjugated anti-epithelial cell adhesion molecule monoclonal antibody against pancreatic carcinoma.
    Moldenhauer G; Salnikov AV; Lüttgau S; Herr I; Anderl J; Faulstich H
    J Natl Cancer Inst; 2012 Apr; 104(8):622-34. PubMed ID: 22457476
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Epithelial cell adhesion molecule (EpCAM) is associated with prostate cancer metastasis and chemo/radioresistance via the PI3K/Akt/mTOR signaling pathway.
    Ni J; Cozzi P; Hao J; Beretov J; Chang L; Duan W; Shigdar S; Delprado W; Graham P; Bucci J; Kearsley J; Li Y
    Int J Biochem Cell Biol; 2013 Dec; 45(12):2736-48. PubMed ID: 24076216
    [TBL] [Abstract][Full Text] [Related]  

  • 9.
    Mousavi A; Sabouri A; Hassanzadeh Eskafi A; Alirahimi E; Kazemi-Lomedasht F; Ghaderi H; Behdani M
    Monoclon Antib Immunodiagn Immunother; 2021 Jun; 40(3):113-117. PubMed ID: 34076502
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EpCAM Aptamer-siRNA Chimera Targets and Regress Epithelial Cancer.
    Subramanian N; Kanwar JR; Kanwar RK; Sreemanthula J; Biswas J; Khetan V; Krishnakumar S
    PLoS One; 2015; 10(7):e0132407. PubMed ID: 26176230
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Primary cervical carcinoma cell lines overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody.
    Richter CE; Cocco E; Bellone S; Bellone M; Casagrande F; Todeschini P; Rüttinger D; Silasi DA; Azodi M; Schwartz PE; Rutherford TJ; Pecorelli S; Santin AD
    Int J Gynecol Cancer; 2010 Dec; 20(9):1440-7. PubMed ID: 21370592
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phenotype-dependent effects of EpCAM expression on growth and invasion of human breast cancer cell lines.
    Martowicz A; Spizzo G; Gastl G; Untergasser G
    BMC Cancer; 2012 Oct; 12():501. PubMed ID: 23110550
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Isolation and characterization of nanobodies against epithelial cell adhesion molecule as novel theranostic agents for cancer therapy.
    Roshan R; Naderi S; Behdani M; Cohan RA; Ghaderi H; Shokrgozar MA; Golkar M; Kazemi-Lomedasht F
    Mol Immunol; 2021 Jan; 129():70-77. PubMed ID: 33183767
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EpCAM is overexpressed in gastric cancer and its downregulation suppresses proliferation of gastric cancer.
    Wenqi D; Li W; Shanshan C; Bei C; Yafei Z; Feihu B; Jie L; Daiming F
    J Cancer Res Clin Oncol; 2009 Sep; 135(9):1277-85. PubMed ID: 19294417
    [TBL] [Abstract][Full Text] [Related]  

  • 15. EpCAM-selective elimination of carcinoma cells by a novel MAP-based cytolytic fusion protein.
    Hristodorov D; Amoury M; Mladenov R; Niesen J; Arens K; Berges N; Hein L; Di Fiore S; Pham AT; Huhn M; Helfrich W; Fischer R; Thepen T; Barth S
    Mol Cancer Ther; 2014 Sep; 13(9):2194-202. PubMed ID: 24980949
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted methylation of the epithelial cell adhesion molecule (EpCAM) promoter to silence its expression in ovarian cancer cells.
    Nunna S; Reinhardt R; Ragozin S; Jeltsch A
    PLoS One; 2014; 9(1):e87703. PubMed ID: 24489952
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic window of an EpCAM/CD3-specific BiTE antibody in mice is determined by a subpopulation of EpCAM-expressing lymphocytes that is absent in humans.
    Amann M; Friedrich M; Lutterbuese P; Vieser E; Lorenczewski G; Petersen L; Brischwein K; Kufer P; Kischel R; Baeuerle PA; Schlereth B
    Cancer Immunol Immunother; 2009 Jan; 58(1):95-109. PubMed ID: 18594818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Production and evaluation of cytotoxic effects of DT386-BR2 fusion protein as a novel anti-cancer agent.
    Shafiee F; Rabbani M; Jahanian-Najafabadi A
    J Microbiol Methods; 2016 Nov; 130():100-105. PubMed ID: 27609715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. EpCAM is overexpressed in local and metastatic prostate cancer, suppressed by chemotherapy and modulated by MET-associated miRNA-200c/205.
    Massoner P; Thomm T; Mack B; Untergasser G; Martowicz A; Bobowski K; Klocker H; Gires O; Puhr M
    Br J Cancer; 2014 Aug; 111(5):955-64. PubMed ID: 24992580
    [TBL] [Abstract][Full Text] [Related]  

  • 20. EpCAM is a putative stem marker in retinoblastoma and an effective target for T-cell-mediated immunotherapy.
    Mitra M; Kandalam M; Harilal A; Verma RS; Krishnan UM; Swaminathan S; Krishnakumar S
    Mol Vis; 2012; 18():290-308. PubMed ID: 22328825
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.